METHOD FOR EVALUATING EFFECTIVENESS OF THERAPY IN VITRO AND IN VIVO IN EXPERIMENTAL MODEL OF IMIQUIMOD-INDUCED PSORIASIS-LIKE DERMATITIS Russian patent published in 2024 - IPC G01N33/53 G09B23/28 C12N5/78 

FIELD: medicine.

SUBSTANCE: invention refers to experimental medicine, namely for preclinical studies of local and systemic drugs, and concerns evaluation of therapeutic effectiveness in a mouse experimental model of imiquimod-induced psoriasis-like dermatitis. Experimental group mice are treated with 1% hydrocortisone ointment in a daily dose of 62.5 mg/cm per animal for 7 days. Cell suspension is obtained from the biopsy materials of the affected skin areas of the mice by splitting skin tissue in a collagenase solution. Further, the cells are washed from enzymes and stained using monoclonal antibodies for flow cytometry; flow cytometry is used to estimate the percentage γδ T-lymphocytes – γδTCR+ cells and Langerhans cells – CD207+ cells in skin. Conducted therapy is considered to be effective in reducing the number of γδ T-lymphocytes by 2 and more times, Langerhans cells CD207+ by no more than 10.5 times and reduction of mPASI index relative to values in groups of mice without treatment.

EFFECT: invention provides a quantitative assessment of the intensity of inflammation in an imiquimod-induced model of psoriasis in mice using a cytofluorimetric analysis of the content γδ T-lymphocytes and CD207+ Langerhans cells in mouse skin for preclinical study.

1 cl, 4 tbl